Risk Factors for Hepatotoxicity in Patients Treated With Highly Active Antiretroviral Therapy
Paolo Bonfanti(University of California San Diego), Tiziana Quirino(Ospedale di Circolo di Busto Arsizio), Ivano Faggion(Fairfield Infectious Diseases Hospital), Canio Martinelli(Azienda Ospedaliero-Universitaria Careggi), Paolo Fortuna(Azienda Ospedaliera San Gerardo), Elena Ricci(Mario Negri Institute for Pharmacological Research), Simona Landonio(ASST Fatebenefratelli Sacco)
Cited by 15
Related Papers
Hospital-Acquired Infections in Critically Ill Patients With COVID-19
|CHEST Journal|2021|404
High rates of 30-day mortality in patients with cirrhosis and COVID-19
|Journal of Hepatology|2020|394
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study
|Clinical Infectious Diseases|2021|264
Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels
|medRxiv|2020|234
Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program
|Clinical Infectious Diseases|2012|208